25834-99-5

Usage

Uses

Used in Pharmaceutical Industry:
4,4-Dimethylcyclohexylamine hydrochloride is used as an intermediate in the synthesis of various pharmaceutical compounds. Its role in organic synthesis allows for the creation of a wide range of medications, making it a valuable component in drug development.
Used in Chemical Manufacturing:
In the chemical manufacturing sector, 4,4-Dimethylcyclohexylamine hydrochloride is used as a reagent and solvent in chemical reactions. Its unique properties enable it to facilitate the production of various chemical products, contributing to the efficiency and effectiveness of manufacturing processes.

InChI:InChI=1/C8H17N/c1-8(2)5-3-7(9)4-6-8/h7H,3-6,9H2,1-2H3

Upstream product

• 4701-96-6 4,4-dimethylcyclohexan-1-one oxime 
• 7440-02-0 nickel 
• 4255-62-3 4,4-dimethylcyclohexane-1-one 
• 1073-13-8 4,4-dimethylcyclohexenone 

Downstream Products

• 33082-83-6 N-<2-Chlor-aethyl>-N'-<4,4-dimethyl-cyclohexyl>-harnstoff 
• 742070-28-6 3-methyl-N-(4,4-DIMETHYLCYCLOHEXYL)-5,6,7,8-tetrahydro-quinoxaline-2-CARBOXAMIDE 
• 934765-67-0 1,1-dimethylethyl({4-[(4-amino-3-nitrophenyl)oxy]phenyl}methyl)(4,4-dimethylcyclohexyl)carbamate 
• 1007573-20-7 3′-({2-[(4,4-dimethylcyclohexyl)amino]ethyl}oxy)-4-biphenylcarboxamide hydrochloride 
• 1008359-56-5 (4,4-dimethylcyclohexyl)({3-[1-(triphenylmethyl)-1H-benzimidazol-5-yl]phenyl}methyl)amine 
• 1008359-55-4 (4,4-dimethylcyclohexyl)({3-[1-(triphenylmethyl)-1H-benzimidazol-6-yl]phenyl}methyl)amine 
• 1008359-57-6 {[3-(1H-benzimidazol-5-yl)phenyl]methyl}(4,4-dimethylcyclohexyl)amine hydrochloride 
• 1449736-83-7 N-(4,4-dimethylcyclohexyl)-8-nitroquinazolin-4-amine 
• 1473450-60-0 NITD-304 
• 1007575-90-7 3′-({[(4,4-dimethylcyclohexyl)methyl]amino}methyl)-2-methyl-4-biphenylcarboxamide hydrochloride 

Relevant academic research and scientific papers

As opioid receptor antagonists or inverse agonists of the novel compounds

Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.

NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS

Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.

Exploring organosilane amines as potent inhibitors and structural probes of influenza a virus M2 proton channel

We describe the use of organosilanes as inhibitors and structural probes of a membrane protein, the M2 proton channel from influenza A virus. Organosilane amine inhibitors were found to be generally as potent as their carbon analogues in targeting WT A/M2

METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS

A method of treatment using pharmaceutical compositions containing novel antagonists or inverse agonists at opioid receptors for the treatment of binge eating disorder, anorexia nervosa, bulimia nervosa, excess drug or alcohol use, or eating disorder not otherwise specified.

NOVEL HETEROCYCLE COMPOUNDS

The present invention relates to novel compounds which are antagonist or inverse agonists at an opioid receptor. Such compounds are useful in the treatment of obesity and related diseases and/or conditions in mammals, particularly humans. Methods of making and using such compounds are also disclosed.

BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS

Compounds of formula (I) or pharmaceutically acceptable salts thereof, are opioid receptor modulators, e.g. mu-opioid receptor antagonists, neutral antagonists or inverse agonists, and are useful inter alia for the treatment of obesity.

BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS

Compounds of formula (I): or pharmaceutically acceptable salts thereof, are opioid receptor modulators, e.g. mu- opioid receptor antagonists, neutral antagonists or inverse agonists, and are useful for the treatment of metabolic disorders including obesity.